# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lili Boulanger (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET025-SYN-TD
- Date: 1915-08-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odile Marchetti-Rowe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review on maintenance risankizumab. **S**

## History of present illness

Ms. Boulanger is six months into risankizumab, with two maintenance doses given, the second at home, and the next due in two weeks. She has one or two formed stools a day, no pain, and no extra-intestinal symptoms (Harvey-Bradshaw Index 1). She has regained 5.6 kg since diagnosis. She is composing a new choral work. She asked about having children one day and how her treatment would affect a pregnancy. **S**

| Element | Detail |
|---|---|
| Interval change | Two maintenance doses; no flares or infections |
| Activity | Harvey-Bradshaw Index 1 |
| Weight | 50.6 kg, BMI 19.8 |
| Question | Pregnancy in the future |
| Work | Composing a new choral work |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or fatigue |
| Gastrointestinal | Negative | One or two formed stools a day |
| Eyes | Negative | No eye pain or redness |
| Musculoskeletal | Negative | No joint pain |
| Genitourinary | Negative | Regular periods |
| Psychiatric | Negative | Mood good; PHQ-9 3 |

6 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugs **S**
- Risankizumab 360 mg in 2.4 mL by subcutaneous on-body injector every 8 weeks (maintenance), from week 12 **S**
- Cholecalciferol (vitamin D3) 1889 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 108/70 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 50.6 kg; BMI 19.8 kg/m². All vital signs are synthetic.

Hemoglobin: 13.1 g/dL; Ferritin: 72 ng/mL; Vitamin B12: 340 pg/mL; CRP: 2 mg/L; Fecal calprotectin: 42 ug/g; Albumin: 4.3 g/dL; PHQ-9: 3. All results are synthetic.

## Change since baseline

- Hemoglobin: 10.6 g/dL (low) at baseline, 13.1 g/dL at this visit **S**
- Ferritin: 9 ng/mL (low) at baseline, 72 ng/mL at this visit **S**
- Vitamin B12: 310 pg/mL at baseline, 340 pg/mL at this visit **S**
- CRP: 38 mg/L (high) at baseline, 2 mg/L at this visit **S**
- Fecal calprotectin: 1240 ug/g (high) at baseline, 42 ug/g at this visit **S**
- Albumin: 3.3 g/dL (low) at baseline, 4.3 g/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; BMI 19.8 |
| Mouth | No ulcers |
| Abdomen | Soft, non-tender; no mass |
| Skin | No erythema nodosum; injection sites clear |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Crohn disease in clinical and biochemical remission** (K50.80). Harvey-Bradshaw Index 1, CRP 2 mg/L, and fecal calprotectin 42 ug/g, normal: the six-month targets are met. Endoscopic healing remains to be confirmed. **S**
   - Continue risankizumab 360 mg every 8 weeks.
   - Ileocolonoscopy in about two months.
   - Vitamin B12 yearly because the terminal ileum is involved; 340 pg/mL today.
2. **Malnutrition, resolved** (E44.0). Weight 50.6 kg (BMI 19.8) and albumin 4.3 g/dL. **S**
   - Supplements stopped; normal varied diet.
3. **Future pregnancy**. Fertility is normal in Crohn disease in remission. Active disease, not the medicine, is the main risk to a pregnancy. Data on risankizumab in pregnancy are limited, unlike anti-TNF drugs; if she plans a pregnancy, the options will be reviewed with her first. **S**
   - Plan pregnancy after at least three to six months of steroid-free remission, with a preconception IBD review.
   - Folic acid 400 micrograms daily from three months before trying.
   - Effective contraception until then if she becomes sexually active.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptoms and Harvey-Bradshaw Index | Every visit | Completed today | 1: remission |
| Laboratory | CRP | Every visit | Completed today | 2 mg/L |
| Laboratory | Fecal calprotectin | About six months after starting treatment, then every 3 to 6 months | Completed today | 42 ug/g, normal: biochemical remission |
| Imaging | Ileocolonoscopy for endoscopic response | Six to twelve months after starting treatment | Ordered | Booked in about two months |
| Laboratory | Hemoglobin, ferritin, and vitamin B12 | Every 6 to 12 months; B12 yearly with ileal disease | Completed today | Hemoglobin 13.1 g/dL, ferritin 72, vitamin B12 340 pg/mL |
| Laboratory | Albumin and weight | Every visit | Completed today | Albumin 4.3 g/dL; weight 50.6 kg |
| Laboratory | Liver enzymes on maintenance risankizumab | Routine after induction | Not indicated | Induction monitoring was completed and normal; no symptoms |
| Survey | Depression screen (PHQ-9) | At least yearly | Completed today | PHQ-9 3 |
| Self-management | Pregnancy planning and contraception | At least yearly in women of reproductive age | Completed today | Counseled; folic acid before conception; preconception review |
| Medication safety | Infection review and vaccines | Every visit | Completed today | No infections since April; influenza vaccine due in the autumn |

## Goal progress

- Reach a diagnosis, with tuberculosis excluded, within two weeks. Outcome by 1915-01-28: Ileocolonoscopy, biopsies, MR enterography, interferon-gamma release assay, and chest X-ray completed in nine days; Crohn disease diagnosed and intestinal tuberculosis made very unlikely, with the mycobacterial culture still pending. **S**
- Steroid-free clinical remission by week 12 to 16 of treatment. Outcome by 1915-04-27: Harvey-Bradshaw Index 2 at week 12, five weeks after the prednisone taper ended. **S**
- Normal CRP and fecal calprotectin by six months, and endoscopic response at six to twelve months. In progress; target 1915-10-05. **S**
- Regain weight to a BMI of 19 or more and correct iron and vitamin D. Outcome by 1915-08-03: Weight 50.6 kg (BMI 19.8); hemoglobin 13.1, ferritin 72, vitamin D 34. **S**
- Perform her March concert and keep composing through treatment. Outcome by 1915-04-27: Composing most mornings; the concert went ahead in late March with a plan for bathroom access. **S**

## Guideline basis

- ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025), American College of Gastroenterology
- ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025), American College of Gastroenterology
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the IOIBD. Gastroenterology 2021;160:1570-1583 (2021), International Organization for the Study of Inflammatory Bowel Diseases
- Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2025;23:S1-S60 (2025), Global Consensus Group on Pregnancy in IBD

## Follow-up

- Ileocolonoscopy in about two months. Adult preventive visit in the autumn. **S**
- Next scheduled visit 1915-10-19: adult preventive visit. **S**
